Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epoprostenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | PPARD | Q03181 | 2/20 | 0.71 |
| ▸ | PPARA | Q07869 | 2/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.56 |
| ▸ | PTGFR | P43088 | 2/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.56 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epoprostenol SCHEMBL551616 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL16783375 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL16783374 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL22607961 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24340812 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL705594 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24033081 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24612535 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL21283002 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL6227411 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205318-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | RESPIRA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | disclosed |
| US-10912778-B2 | Methods for treatment of pulmonary hypertension | Respira Therapeutics, Inc. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200093830-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. | 2020-03-26 | — | — | US | disclosed |
| US-20170043151-A1 | LEAK REDUCTION DURING IMPLANTABLE INFUSION DEVICE REFILL | MEDTRONIC, INC. | 2017-02-16 | — | — | US | disclosed |
| US-8598227-B2 | Epoprostenol formulation and method of making thereof | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-03 | — | — | US | disclosed |
| US-20130018093-A1 | NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-17 | — | — | US | disclosed |
| US-8318802-B2 | Epoprostenol formulation and method of making thereof | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20090088468-A1 | NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
| US-20050003017-A1 | Hypotensive and hypertensive properties of renomedullar extracts | GLODNY BERNHARD (DE) | 2005-01-06 | — | — | US | disclosed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | disclosed |
| US-4479944-A | SOLVENT, CLATHRATE | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
| US-4479966-A | 6,9-Methano-PGI2 analogues | ONO PHARMACEUTICAL COMPANY, LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
| US-4464388-A | TO LIVER, KIDNEYS OR PANCREAS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4399147-A | Prostaglandin 12 analogues and their pharmaceutical compositions | ONO PHARMACEUTICAL CO. LTD. (JP) | 1983-08-16 | — | — | US | disclosed |
| US-4367237-A | THIOPGI-1 DERIVATIVES; OXYTOCICS; PREFERENTIAL | ONO PHARMACEUTICAL CO., LTD. (JP) | 1983-01-04 | — | — | US | disclosed |
| US-4313954-A | 6,9-Nitrilo-prostaglandin analogues | ONO PHARMACEUTICAL CO. LTD. (JP) | 1982-02-02 | — | — | US | disclosed |
| US-4234597-A | 6,9-Nitrilo(imino)-prostaglandin analogues | ONO PHARMACEUTICAL CO. LTD. (JP) | 1980-11-18 | — | — | US | disclosed |
| US-4232009-A | PROSTAGLANDINS, CYCLODEXTRIN CLATHRATES, HYPOTENSIVES | ONO PHARMACEUTICAL CO. LTD. (JP) | 1980-11-04 | — | — | US | disclosed |
| US-4207332-A | Prostaglandin I2 analogues | ONO PHARMACEUTICAL CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
| US-4178367-A | Prostaglandin I2 analogues | ONO PHARMACEUTICAL CO. LTD. (JP) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088468-A1 | NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF | PTGIS, PTGER1, PTGIR | PTGIR 3/4885ALDH1A1 1060/4885MEN1 2731/4885 |
| US-20130018093-A1 | NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF | PTGIS, PTGER1, PTGIR | PTGIR 3/4885ALDH1A1 1060/4885MEN1 2731/4885 |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | PTGIR 253/4885ALDH1A1 2724/4885MEN1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.